Chemistry after lung removal. Effectiveness of lung cancer treatment with chemotherapy. Drugs and nutrition. When and how is chemotherapy prescribed?

Asthenic syndrome belongs to the group of psychopathological disorders and is characterized by gradual development. Mental illness develops against the background of many chronic diseases. Asthenic disorder is characterized by frequent headaches and dizziness, decreased performance, increased irritability, and drowsiness.

What is asthenic syndrome?

Asthenic condition is a psychopathological disorder in which the patient complains of fatigue, weakness, irritability and other disorders in the functioning of the nervous system. This condition is considered one of the most common, as it develops against the background of many pathologies of internal organs and systems, it develops both in adults and.

Symptoms caused by asthenic syndrome are permanent. Increased fatigue, which is the main symptom of this psychopathological disorder, does not disappear after a long rest, therefore, it requires therapeutic intervention.

This syndrome differs from ordinary fatigue, which is of a short-term nature and occurs against the background of physical and mental overload, malnutrition and other reasons.

Asthenia is diagnosed when its symptoms bother the patient for several months or years.

Reasons for the development of asthenia

In about 45% of patients with asthenia, the causes of its development are due to organic damage to internal organs and systems. The risk group includes people with diseases of the cardiovascular system:

  • hypertension of various etiologies;
  • ischemic heart disease;
  • myocardial infarction;
  • carditis;
  • arrhythmia.

Asthenic disorder can also be provoked by: deficiency of nutrients supplied to the central nervous system, excessive energy expenditure, metabolic disorders.

Asthenic manifestations are diagnosed against the background of pathologies of the digestive tract:

  • dyspeptic disorders;
  • pancreaduodenitis;
  • peptic ulcer;
  • gastroenterocolitis.

The appearance of asthenia is promoted by diseases of the genitourinary system: cystitis, chronic kidney pathologies, glomerulonephritis, pyelonephritis.

Possible causes of asthenia include disorders in the endocrine system caused by hypo- and hyperthyroidism, diabetes mellitus, and diseases of the adrenal glands.

Asthenic depression often develops after childbirth or due to hormonal changes in the body.

Organic reasons also include:

  • systemic pathologies;
  • allergic reaction;
  • oncological diseases;
  • congenital diseases of the kidneys, heart, lungs;
  • hepatitis of various types;
  • tuberculosis;
  • meningitis;
  • encephalitis;
  • SARS;
  • autoimmune diseases.

In addition, vegetovascular asthenia is distinguished, which occurs against the background of VVD.

In addition to organic causes, asthenia leads to the cessation of taking a number of drugs (withdrawal syndrome), the refusal of alcohol or cigarettes, severe stress, prolonged and excessive physical exertion.

Asthenic disorder affects people with low intelligence, living in remote settlements or with dementia. In this case, the cause of the psychopathological condition lies in irreversible changes affecting the brain. Vascular diseases (atherosclerosis) also lead to such disorders.

Classification of asthenic syndrome

Depending on the causes of occurrence, functional and somatogenic (somatic) asthenia are distinguished. Both forms of violation occur with approximately the same frequency.

Functional asthenia is temporary and reversible. This form of disorder develops due to psycho-emotional or physical overload, stress, acute infectious diseases.

Somatogenic asthenia occurs as a result of a prolonged course of chronic diseases.

Depending on the characteristics of the asthenic syndrome, its course is divided into:

  1. Acute. In fact, this is another name for functional asthenia. It develops under the influence of severe stress or an infectious disease.
  2. Chronic. This type of disease is characterized by a long course.

Asthenic disorder is also divided into two types, taking into account both causative factors and features of the clinical picture:

  1. Senile. This type of disorder is mainly diagnosed in the elderly. Senile asthenia usually develops as a result of vascular pathologies that cause brain damage and provoke the appearance of dementia.
  2. Neurocirculatory. The cause of asthenia is vegetovascular dystonia.

In addition to these types of classifications, asthenia is divided into 2 forms depending on the characteristics of clinical manifestations:

  1. Hypersthenic. Characterized by increased irritability. Patients with this form of impairment cannot tolerate strong odors, strong sounds, or bright lights.
  2. Hyposthenic. The development of this form of asthenic syndrome is accompanied by a decrease in the body's response to external stimuli. As a result, patients experience drowsiness, lethargy, and a state of apathy.

Severe brain pathologies caused by infection or other causes often cause the development of an organic emotionally labile asthenic disorder. This form of the disorder is characterized by sudden mood swings and emotional incontinence.

Organic brain damage provokes the development of such a form of disorder as encephalosthenic syndrome. This type of disorder is characterized by the following symptoms:

  • inability to remember information;
  • decrease in working capacity;
  • weakening of the will;
  • decreased intelligence;
  • inability to adapt.

With encephalosthenic syndrome, total dementia is often diagnosed.

To determine how to treat asthenia, it is necessary to establish the cause of its occurrence and it is often possible to identify it by the characteristics of the clinical picture.

Symptoms of asthenia

The symptoms of asthenia are varied. The first signs of asthenia occur during the day. Moreover, the symptoms that develop in the late afternoon are more pronounced.

The main symptom of functional asthenia is severe fatigue. Patients quickly get tired when doing any business, and the previous performance is not restored even after a long rest. People with asthenic disorder note in themselves:


To solve problems, patients have to constantly take short breaks. As a result, against the background of such disorders, asthenic depression develops, which is characterized by the following symptoms:

  • decrease in self-esteem;
  • constant anxiety;
  • anxiety state.

As the asthenic syndrome develops, the symptoms are supplemented by signs of psychoemotional disorders. Their appearance is explained by problems that arise due to a decrease in performance. This leads to patients becoming irritable and tense. Psycho-emotional disorders are characterized by a sharp change in mood, the predominance of optimistic or pessimistic views. The progression of asthenia causes depressive neurosis.

Associated symptoms

The development of a psychopathological disorder in most patients is accompanied by dysfunction of the autonomic system, which manifests itself in the form of the following symptoms:


Asthenia is often accompanied by:

  • prolonged headaches;
  • decreased libido in men;
  • sleep disturbance.

Patients with asthenic syndrome are disturbed by bad dreams. Patients often wake up during the night. After waking up, patients have weakness, which increases in the evening.

With asthenia, an increase in body temperature up to 38 degrees and an increase in peripheral (cervical, axillary and other) lymph nodes is possible.

Neurocirculatory disorder

A neurocirculatory disorder that occurs against the background of dysfunction of the autonomic system is characterized by multiple symptoms. Each sign of a pathological disorder is combined into several syndromes:

  1. Cardiac. It is diagnosed on average in 90% of patients with this disease. The development of cardiac syndrome is accompanied by pain sensations that are localized in the chest. At the same time, the appearance of a symptom is not associated with dysfunction of the heart muscle.
  2. Sympathicotonic. This syndrome is characterized by the presence of tachycardia, jumps in blood pressure, blanching of the skin and motor excitation.
  3. Vagotonic. Has a weak heartbeat. With vagotonic syndrome, low blood pressure is observed, which provokes headaches, dizziness, hyperhidrosis, and intestinal upset.
  4. Mental. The syndrome manifests itself in the form of unreasonable bouts of fear and mood swings.
  5. Asthenic. Patients with this syndrome react sharply to changing weather conditions and quickly get tired.
  6. Respiratory. Patients experience difficulty breathing (feeling short of breath).

For neurocircular asthenia, the appearance of several syndromes at the same time is characteristic.

Symptoms depending on the causative factor

Neurotic disorders that cause asthenic syndrome manifest themselves in the form of increased muscle tone, which is why patients complain of constant weakness.

In vascular pathologies, the brain experiences an acute need for nutrients. Such violations provoke a decrease in muscle tone and slow thinking.

Oncological diseases of the brain and organic damage to its tissues cause:


With organic lesions of the brain, the symptoms are persistent and prolonged.

Similar clinical phenomena occur after CNS injuries. In this case, it is possible to attach clinical manifestations of vegetative disorders. Moreover, the symptoms of VVD become more pronounced during the course of respiratory and other diseases.

The asthenic syndrome that occurs against the background of ARVI manifests itself as a hypersthenic disorder, in which there is increased irritability and nervousness. If the respiratory disease becomes severe, the disorder takes on a hyposthenic form. With this development, there is a gradual decrease in cognitive functions and performance.

Diagnosis of asthenic manifestations

Due to the fact that with asthenic syndrome there are multiple symptoms characteristic of various mental disorders, this nervous pathology is difficult to diagnose.

To accurately determine the disease, the patient is tested, during which it is necessary to answer more than 10 questions. The results of the survey show the presence or absence of symptoms characteristic of asthenia.

Psychopathological disorder must be differentiated from other similar disorders:

  • hypochondriacal neurosis;
  • hypersomnia;
  • depressive neurosis.

In this case, additional research helps to identify the cause. Asthenic syndrome is diagnosed by a series of laboratory tests:


If CNS or VSD is suspected, an MRI of the brain is prescribed. Additional examinations are also carried out to identify violations in the work of other organs.

How to treat asthenia?

Treatment of asthenia is carried out under the condition that other forms of disorders characterized by similar clinical manifestations are excluded. The treatment regimen is selected taking into account the disease that caused the asthenic disorder.

To cure asthenia, the patient must make significant lifestyle adjustments. It is important to avoid stressful situations until full recovery. For this, patients are often prescribed treatment in a sanatorium.

Medications help to get rid of asthenia, the action of which is aimed at eliminating the disease that caused this disorder. Treatment with medicines, depending on the nature of the pathology, is carried out under the supervision of a physician, and it is mandatory if therapy for asthenia is prescribed for VVD.

Medicines are prescribed according to the prescription of a specialist and for treatment at home.

Medical therapy

Drugs are selected taking into account the cause and the nature of the symptoms of the disease. At the initial stage of treatment, drugs are used in the minimum dosage.

Functional asthenia is treated with nootropics:


Nootropics are used for severe cognitive impairment. These medicines are recommended to be supplemented with adaptogens, which include extracts:

  • ginseng;
  • Rhodiola rosea;
  • lemongrass;
  • eleutherococcus.

A good result is demonstrated by anti-asthenic drugs with a sedative effect: Novo-Passit, Sedasen.

Asthenic depression, depending on the complexity, is treated with antidepressants or tranquilizers. The first group of drugs includes:


Of the tranquilizers for asthenia, Phenibut, Atarax, and Clonazepam are used. Antidepressants and tranquilizers are allowed to be used only after consulting a doctor.

In case of organic asthenic disorder and other forms of psychopathological condition, antipsychotics (Teralen, Eglonil) and B vitamins are also prescribed.

Regardless of the form of asthenia, symptoms and treatment, a set of measures must be applied for the successful recovery of the patient. Pills do not help if the patient does not make lifestyle adjustments.

Psychotherapeutic treatment

Asthenic disorders are successfully treated through psychotherapeutic therapy. In this case, various methods are used:

  1. Influencing the general condition of the patient and eliminating individual manifestations of anxiety-asthenic syndrome. To achieve the desired result, methods of self-hypnosis, hypnosis, auto-training and others are used. Such treatment of asthenic syndrome in adults reduces anxiety and improves the patient's condition.
  2. Methods affecting the mechanisms of development of the disorder. Asthenic syndrome is treated with the help of cognitive-behavioral therapy, neuro-linguistic programming.

If necessary, psychotherapeutic techniques are used, through which the factor of the appearance of the disorder is eliminated. This approach allows you to identify the relationship between certain events (for example, conflicts within the family) and the development of asthenia.

Non-drug treatments

With asthenia, treatment should be comprehensive. Already at the initial stage, patients need:

  • get rid of bad habits;
  • normalize rest and work schedules;
  • avoid conflict situations;
  • do physical exercise daily.

By following the rules above, you can get rid of such a disorder as asthenic depression.

In addition to the above methods of treatment, physiotherapeutic measures are used:

  • sharko shower;
  • phototherapy;
  • acupuncture;
  • massage and others.

Non-drug methods of treatment are unable to fully combat organic asthenic disorder. However, this approach helps to reduce the intensity of symptoms characteristic of this type of psychopathological disorder.

Prevention of asthenic phenomena

Understanding the features of asthenia, what kind of disease it is, helps to independently choose measures to prevent this mental disorder. To avoid its development, it is necessary to treat any diseases in a timely manner.

Asthenic conditions often occur against the background of physical and mental overwork, therefore, for the purpose of prevention, it is recommended to fully rest and sleep at least 7-8 hours a day. If necessary, you can take drugs that strengthen the immune system and tone the nervous system.

Asthenic reactions respond well to treatment with timely seeking help from a doctor. The prolonged development of asthenic syndrome gives complications in the form of neurosis, schizophrenia and chronic depression.

2738

The course of chemotherapy lasts cyclically, for several days. Usually it is prescribed in tablets, administered intravenously, but sometimes it is done on an outpatient basis. After that, doctors give a few days for the patient's body to recover from side effects. At this time, doctors are actively studying the effects of chemotherapy in lung cancer, and then decide whether and how to continue.

In the world there are more than 60 types of drugs for the treatment of cancer. Here are the most used ones, as well as their combinations:

  • Carboplantin and paclitaxel;
  • Vinoreobin and cyplastin/carboplantin;
  • gemcitabine and cyplastin/carboplatin;
  • mitomycin, ifosfamide and cisplatin;
  • Etopoposit and carboplatin.

The course of chemotherapy for each is selected for each individual, depending on the characteristics of the body and based on the characteristics of the type of cancer.

As soon as the patient has gone all the way to recovery, he is prescribed a fairly strict diet, which is vital to follow. Although in fact, in the vast majority of cases, limited nutrition during chemotherapy is present throughout the entire process. Small meals are also important.

Here is the main list of foods strictly prohibited when eating after chemotherapy:

  • Food containing a large amount of sugar or its substitute (sweets, pastries);
  • Food with preservatives/additives;
  • Alcohol and strong drinks (coffee, cocoa);
  • Fatty, fried food;
  • Smoked foods (sausage, fish), any marinades are poorly digested.

As for what is possible with nutrition after chemotherapy, the list is very small:

  • Chicken eggs;
  • Dairy products;
  • Peanut butter, almonds, soy and beans;
  • Fruits/boiled vegetables: from tomatoes to apricots;
  • Various greens;
  • Of meat, only poultry and rabbit meat;
  • Green tea, herbal tinctures, carefully purified water.

Eating like this during or after chemotherapy for lung cancer certainly has a huge impact on weight. The body is rapidly losing the substances it needs, the person is losing weight. In order to recover and restore body weight to the optimal value at an accelerated pace, doctors recommend focusing on foods containing a large amount of protein. It is also mandatory to add seasonings such as curry, oregano, cinnamon to them, so the patient will return the sensation of taste.

Chemotherapy is used extremely intensively, since in this case metastases quickly spread throughout the body. In the last phase of the disease, a person begins to have difficulty speaking and the ability to swallow, move, puffiness of the neck, chest, head, limbs (superior vena cava syndrome) is formed.

In this case, chemotherapy is the main expensive way to recover from non-small cell cancer, which can also be combined with radiation or radiotherapy.

Two drug lines for stage 4 lung cancer

  1. The first line is distinguished by the following feature - treatment is started with a mixture of platinoids, gemcitabine, vinorelbine and several other drugs. Experience has shown that it is in this way, and not by using one drug at a time, that the maximum effect is achieved.
  2. The second line is used if oncology is completely indifferent to the above methods of treatment. Then specialists prescribe to patients the same platenoids, but with the addition of Docetaxel or targeted mixtures. These drugs do not have any side effects, since they provide for the absence of toxic effects on the body.

As for the special diet for lung cancer at the last 4th stage , then it does not change.

The dietary menu is strictly observed at any stage, both during treatment and for an individually set time after recovery.

RCHD (Republican Center for Health Development of the Ministry of Health of the Republic of Kazakhstan)
Version: Clinical Protocols of the Ministry of Health of the Republic of Kazakhstan - 2015

Malignant neoplasm of bronchi and lung (C34)

Oncology

general information

Short description

Recommended
Expert Council
RSE on REM "Republican Center
health development"
Ministry of Health
and social development
Republic of Kazakhstan
dated October 30, 2015
Protocol #14

Lung cancer - a tumor of epithelial origin, developing in the mucous membrane of the bronchi, bronchioles and mucous bronchial glands. (UD-A)


Protocol name: Lung cancer.


Protocol code:

ICD code(s) - 10:
C 34 Malignant neoplasm of bronchi and lung.

Abbreviations used in the protocol:


ALTalanine aminotransferase
ASTaspartate aminotransferase
APTTactivated partial thromboplastin time
WHOWorld Health Organization
i/vintravenously
i/mintramuscularly
Grgray
EDunits
gastrointestinal tractgastrointestinal tract
ZNOmalignant neoplasm
IGHimmunohistochemical study
ELISAlinked immunosorbent assay
CTCT scan
LTradiation therapy
MRIMagnetic resonance imaging
NSCLCnon-small cell lung cancer
UACgeneral blood analysis
OAMgeneral urine analysis
PATpositron emission tomography
GENUSsingle focal dose
SODtotal focal dose
CCCthe cardiovascular system
UZDGultrasound dopplerography
ultrasoundultrasonography
ECGelectrocardiogram
echocardiographyechocardiography
TNMTumor Nodulus Metastasis - international classification of stages of malignant neoplasms

Date of development/revision of the protocol: 2015

Protocol Users: oncologists, surgeons, therapists, general practitioners, pulmonologists, phthisiatricians.

Evaluation of the degree of evidence of the given recommendations.
Evidence level scale:


A High-quality meta-analysis, systematic review of RCTs, or large RCTs with a very low probability (++) of bias, the results of which can be generalized to the appropriate population.
IN High-quality (++) systematic review of cohort or case-control studies or high-quality (++) cohort or case-control studies with very low risk of bias or RCTs with not high (+) risk of bias, the results of which can be extended to the appropriate population.
WITH Cohort or case-control or controlled trial without randomization with low risk of bias (+).
The results of which can be generalized to the relevant population or RCTs with a very low or low risk of bias (++ or +), the results of which cannot be directly generalized to the appropriate population.
D Description of a case series or uncontrolled study, or expert opinion.
GPP Best Pharmaceutical Practice.

Classification


Clinical classification: (the most common approaches, for example: by etiology, by stage, etc.).

HISTOLOGICAL CLASSIFICATION (UD-A):

· Squamous cell carcinoma (epidermoid)
1. papillary
2. clear cell
3. small cell
4. basalioid
· small cell cancer
1. combined small cell carcinoma
· Adenocarcinoma
1. mixed cell adenocarcinoma
2. acinar adenocarcinoma
3. papillary adenocarcinoma
4. bronchioloalveolar adenocarcinoma
mucosal
non-mucosal
mixed
5. solid adenocarcinoma with mucus production
fetal
Mucinous (colloidal)
mucinous cystadenocarcinoma
clear cell
round cell
Large cell cancer
1. neuroendocrine
mixed large cell
basalioid carcinoma
lymphoepithelioma-like cancer
Giant cell carcinoma with rhabdoid phenotype
clear cell carcinoma
Glandular squamous cell carcinoma
· Sarcomatoid carcinoma
1. polymorphic carcinoma
2. spindle cell carcinoma
3. giant cell carcinoma
4. carcinosarcoma
5. pulmonary blastoma
· Carcinoid tumor
1.typical
2.atypical
Cancer of the bronchial glands
1. adenoid cystic cancer
2. mucoepidermoid cancer
3. epithelial myoepithelial cancer
Squamous cell carcinomain situ
mesenchymal tumors.
1. epithelial hemangioendothelioma
2.angiosarcoma
3.pleuropulmonary blastoma
4.chondroma
5.peribronchial myofibroblastic tumor
Diffuse pulmonary lymphangiomatosis
1.inflammatory myofibroblastic tumor
2. lymphangleiomyommatosiomatosis
3. synovial sarcoma
monophasic
biphasic
1. pulmonary arterial sarcoma
2.pulmonary venous sarcoma

TNM CLASSIFICATION OF LUNG CANCER (UD-A)

Anatomical regions
1. Main bronchus
2. Upper lobe
3. Average share
4. Lower share
Regional lymph nodes
Regional lymph nodes are intrathoracic nodes (nodes of the mediastinum, hilum of the lung, lobar, interlobar, segmental and subsegmental), nodes of the scalene muscle and supraclavicular lymph nodes.

Determination of the spread of the primary tumor (T)

T X- the primary tumor cannot be assessed or the presence of the tumor is proven by the presence of malignant cells in the sputum or flushing from the bronchial tree, but the tumor is not visualized by radiation methods or bronchoscopy.
T0- no evidence of primary tumor
TIS- carcinoma in situ
T1- Tumor less than 3 cm in greatest dimension, surrounded by lung tissue or visceral pleura, without bronchoscopically confirmed invasion of the proximal portions of the lobar bronchi (i.e. without involvement of the main bronchi) (1)
T1a- Tumor no more than 2 cm in greatest dimension (1)
T 1 b- tumor more than 2 cm, but not more than 3 cm in the greatest dimension (1)
T 2 - a tumor larger than 3 cm but not larger than 7 cm, or a tumor with any of the following characteristics (2) :
It affects the main bronchi at least 2 cm from the carina of the trachea;
Tumor invades visceral pleura
Associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung.
T 2 a Tumor more than 3 cm but not more than 5 cm in greatest dimension
T 2 b Tumor larger than 5 cm but not larger than 7 cm in greatest dimension
T 3 Tumor larger than 7 cm or directly invading any of the following structures: chest wall (including tumors of the superior sulcus), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or affecting the main bronchi less than 2 cm from the carina of the trachea (1), but without affecting the latter; or associated with atelectasis or obstructive pneumonitis of the entire lung or with isolated tumor nodule(s) in the same lung lobe as the primary tumor
T 4 - a tumor of any size, growing into any of the following structures: mediastinum, heart, large vessels, trachea, esophagus, vertebral bodies, tracheal carina; the presence of a separate tumor node (nodes) in the lobe of the lung, opposite the lobe with the primary tumor

Regional lymph node involvement (N)

NX- regional lymph nodes cannot be assessed
N0- no metastases in regional lymph nodes
N 1- Metastasis in the peribronchial lymph node and / or in the hilar node of the lung and intrapulmonary nodes on the side of the lesion of the primary tumor, including direct spread of the tumor
N 2- metastases in the nodes of the mediastinum and / or lymph nodes under the carina of the trachea on the side of the lesion
N 3- metastases in the nodes of the mediastinum, the nodes of the gate of the lung on the side opposite to the primary tumor, ipsilateral or contralateral nodes of the scalene muscle or supraclavicular lymph nodes (node)

Distant metastases (M)

M 0- no distant metastases
M 1- there are distant metastases
M 1a- a separate tumor node (nodes) in another lung; tumor with nodules on the pleura or malignant pleural or pericardial effusion (3)
M 1b- distant metastases

Note: (1) A rare, superficially spreading tumor of any size that grows proximal to the main bronchi and an invasive component that is confined to the bronchial wall is classified as T1a.
(2) Tumors with these characteristics are classified as T 2 a , if they measure no more than 5 cm or if the size cannot be determined, and how T 2 b , if the size of the tumor is more than 5 cm, but not more than 7 cm.
(3) Most pleural (pericardial) effusions in lung cancer are due to the tumor. However, in some patients, multiple microscopic examinations of the pleural (pericardial) fluid are negative for tumor elements, and the fluid is also not blood or exudate. These data, as well as the clinical course, indicate that such an effusion is not associated with a tumor and should be excluded from the staging elements, and such a case should be classified as M0.

G - histopathological differentiation
G X- degree of differentiation cannot be determined
G1- highly differentiated
G2- moderately differentiated
G3- poorly differentiated
G4- undifferentiated

pTNM pathological classification
pT, pN and pM categories correspond to T, N and M categories.
pN0 - histological examination of the removed lymph nodes of the root of the lung and mediastinum should usually include 6 or more nodes. If the lymph nodes are not affected, then this is classified as pN0, even if the number of nodes examined is less than usual.
Distant metastases
The categories M1 and pM1 can be further defined according to the following notation



Rclassification
The absence or presence of residual tumor after treatment is described by the symbol R:
R X- the presence of a residual tumor cannot be assessed,
R 0 - no residual tumor
R 1 - microscopic residual tumor,
R 2 - macroscopic residual tumor.

Classification of stages of lung cancer:
Hidden cancer - TxN0M0
Stage 0 - TisN0M0
Stage IA - T1a-bN0M0
Stage IB - T2aN0M0
Stage IIA - T2bN0M0, T1a-bN1M0, T2aN1M0
Stage IIB - T2bN1M0, T3N0M0
Stage IIIA - T1a-bN2M0, T2a-bN2M0, T3N1-2M0, T4N0-1M0
Stage IIIB - T4N2M0, T1-4N3M0
Stage IV - T1-4N0-3M1


Diagnostics


The list of basic and additional diagnostic measures:
The main (mandatory) diagnostic examinations carried out at the outpatient level:
Collection of complaints and anamnesis;
General physical examination;




Additional diagnostic examinations performed at the outpatient level:


Fibroesophagoscopy;



Computed tomography of the brain;
· Positron emission tomography (PET) + computed tomography of the whole body.

The minimum list of examinations that must be carried out upon referral for planned hospitalization: in accordance with the internal regulations of the hospital, taking into account the current order of the authorized body in the field of healthcare.

The main (mandatory) diagnostic examinations carried out at the inpatient level (in case of emergency hospitalization, diagnostic examinations are carried out that were not performed at the outpatient level):
· General blood analysis;
Biochemical blood test (protein, creatinine, urea, bilirubin, ALT, AST, blood glucose);
· Coagulogram (prothrombin index, fibrinogen, fibrinolytic activity, thrombotest);
· General urine analysis;
X-ray of the chest organs (2 projections);
Computed tomography of the chest and mediastinum;
Fibrobronchoscopy diagnostic;
Ultrasound of supraclavicular, axillary lymph nodes;
· Spirography;
· Electrocardiographic study;
ECHO cardiography (after consultation with a cardiologist for patients aged 50 years and older, as well as patients younger than 50 years with concomitant pathology of the cardiovascular system).

Additional diagnostic examinations performed at the inpatient level (in case of emergency hospitalization, diagnostic examinations not performed at the outpatient level are performed):
· Magnetic resonance imaging of the chest with contrast;
Ultrasound of supraclavicular and cervical lymph nodes;
Complex ultrasound diagnostics (liver, gallbladder, pancreas, spleen, kidneys);
Puncture / aspiration biopsy under ultrasound control;
Fibroesophagoscopy;
Open biopsy of enlarged supraclavicular and cervical lymph nodes (in the presence of enlarged lymph nodes);
· Cytological examination;
· Histological examination.

Diagnostic measures taken at the stage of emergency care: No.

Diagnostic Criteria for Making a Diagnosis
complaints and anamnesis
clinical manifestations depending on the stage and localization:
cough with or without sputum
The presence or absence of streaks of blood in the sputum (hemoptysis)
shortness of breath on exertion
· weakness
night sweats
subfebrile temperature
weight loss.
Anamnesis: symptoms lung cancer are nonspecific, therefore characteristic of many diseases of the respiratory system. That is why the diagnosis in many cases is not timely. The tumor in the initial stage is asymptomatic due to the absence of pain endings in the lung tissue. When the tumor grows into the bronchus, a cough appears, initially dry, then with light sputum, sometimes with an admixture of blood. There is hypoventilation of the lung segment and then its atelectasis. Sputum becomes purulent, which is accompanied by fever, general malaise, shortness of breath. Cancer pneumonia joins. Cancerous pleurisy, accompanied by pain syndrome, can join cancerous pneumonia. If the tumor sprouts the vagus nerve, hoarseness joins due to paralysis of the vocal muscles. Damage to the phrenic nerve causes paralysis of the diaphragm. Germination of the pericardium is manifested by pain in the region of the heart. The defeat of the tumor or its metastases of the superior vena cava causes a violation of the outflow of blood and lymph from the upper half of the trunk, upper limbs, head and neck. The patient's face becomes puffy, with a cyanotic tinge, veins swell on the neck, arms, and chest.

Physical examination
Decreased breathing on affected side
hoarseness of voice (during the germination of the tumor of the vagus nerve)
puffiness of the face, with a cyanotic tinge, swollen veins on the neck, arms, chest (with tumor invasion of the superior vena cava)

Laboratory research
· Cytological examination(an increase in the size of the cell up to gigantic, a change in the shape and number of intracellular elements, an increase in the size of the nucleus, its contours, a different degree of maturity of the nucleus and other elements of the cell, a change in the number and shape of the nucleoli);
· Histological examination(large polygonal or spike-shaped cells with well-defined cytoplasm, rounded nuclei with clear nucleoli, with mitoses, cells are arranged in the form of cells and strands with or without keratin formation, the presence of tumor emboli in the vessels, the severity of lymphocytic-plasmacytic infiltration, mitotic activity of tumor cells ).

Instrumental Research
X-ray examination
Peripheral cancer is characterized by fuzziness, blurring of the contours of the shadow. Tumor infiltration of the lung tissue leads to the formation of a kind of radiance around the node, which can be detected only in one of the edges of the neoplasm.
In the presence of peripheral lung cancer, a path can be detected that connects the tumor tissue with the shadow of the root, due to either lymphogenous spread of the tumor, or its peribronchial, perivascular growth.
X-ray picture in central cancer - the presence of tumor masses in the region of the root of the lung; hypoventilation of one or more segments of the lung; signs of valvular emphysema of one or more segments of the lung; atelectasis of one or more segments of the lung.
X-ray picture in apical cancer is accompanied by Pancoast's syndrome. It is characterized by the presence of a rounded formation of the lung apex, pleural changes, destruction of the upper ribs and corresponding vertebrae.
Fibrobronchoscopy
The presence of a tumor in the lumen of the bronchus completely or partially obstructing the lumen of the bronchus.

Pproviding for expert advice:
· Consultation with a cardiologist (for patients aged 50 years and older, as well as patients under 50 years of age in the presence of concomitant pathology of the cardiovascular system);
· Consultation of a neuropathologist (for cerebrovascular disorders, including strokes, brain and spinal cord injuries, epilepsy, myasthenia gravis, neuroinfectious diseases, as well as in all cases of loss of consciousness);
· Consultation of a gastroenterologist (in the presence of concomitant pathology of the gastrointestinal tract in history);
· Consultation of a neurosurgeon (in the presence of metastases in the brain, spine);
· Consultation of an endocrinologist (if there is a concomitant pathology of the endocrine organs).
· Consultation of a nephrologist - in the presence of pathology from the urinary system.
· Consultation of a phthisiatrician - in case of suspected pulmonary tuberculosis.

Differential Diagnosis

Treatment abroad

Get treatment in Korea, Israel, Germany, USA

Get advice on medical tourism

Treatment


Treatment Goals:
Elimination of the tumor process;
Achieving stabilization or regression of the tumor process;
Prolongation of the patient's life.

Treatment tactics:

Non-small cell cancer

Stage
diseases
Treatment Methods
StageIA
(T1a-bN0M0)
StageIB
(T2aN0M0)
Radical operation - lobectomy (extended operation).
StageII A
(T2bN0M0,
T1a-bN1M0, T2aN1M0)
StageII B
T2bN1M0, T3N0M0

Reconstructive plastic surgery with lymph node dissection .
Radiation therapy.
Chemotherapy.
StageIIIA
(T1a-bN2M0,
T2a-bN2M0,
T3N1-2M0,
T4N0-1M0)
Radical surgery - lobectomy, bilobectomy, pneumonectomy combined with lymph node dissection.
Pre- and postoperative radiation and chemotherapy Reconstructive plastic surgery with lymph node dissection, adjuvant chemoimmunotherapy .
StageIIIB
(T4N2M0,
T1-4N3M0)
Chemoradiotherapy
StageIV
(T1-4N0-3M1)
Palliative chemoradiotherapy + symptomatic treatment

small cell cancer

Stage
diseases
Treatment Methods
StageIA
(T1a-bN0M0)
StageIB
(T2aN0M0)

Radical operation - lobectomy with lymph node dissection.
Adjuvant chemotherapy (EP, EU regimens 4 courses with an interval of 3 weeks)
StageII A
(T2bN0M0,
T1a-bN1M0, T2aN1M0)
StageII B
T2bN1M0, T3N0M0)
Preoperative polychemotherapy.
Radical surgery - lobectomy, bilobectomy combined with lymph node dissection.
Reconstructive plastic surgery
Chemoradiotherapy
StageIIIA
(T1a-bN2M0,
T2a-bN2M0,
T3N1-2M0,
T4N0-1M0)
StageIIIB
(T4N2M0,
T1-4N3M0)
Chemoradiotherapy
StageIV
(T1-4N0-3M1)
Palliative chemoradiotherapy.

Non-drug treatment:
Motor modes used in hospitals and hospitals are divided into:
I - strict bed, II - bed, III - ward (semi-bed) and IV - free (general).
· When conducting neoadjuvant or adjuvant chemotherapy - mode III (ward). In the early postoperative period - mode II (bed), with its further expansion to III, IV as the condition improves and the sutures heal.
Diet. For patients in the early postoperative period - hunger, with the transition to table number 15. For patients receiving chemotherapy table - No. 15

Medical treatment:
Chemotherapy:
There are several types of chemotherapy, which differ in purpose of appointment:
· Neoadjuvant tumor chemotherapy is prescribed before surgery, in order to reduce the inoperable tumor for surgery, as well as to identify the sensitivity of cancer cells to drugs for further prescription after surgery.
Adjuvant chemotherapy is given after surgery to prevent metastasis and reduce the risk of recurrence.
Therapeutic chemotherapy is prescribed to reduce metastatic cancerous tumors.
Depending on the location and type of tumor, chemotherapy is prescribed according to different schemes and has its own characteristics.

Indications for chemotherapy:
Cytologically or histologically verified mediastinal malignancies;
in the treatment of unresectable tumors;
Metastases in other organs or regional lymph nodes;
tumor recurrence;
· a satisfactory picture of the patient's blood: normal hemoglobin and hemocrit, the absolute number of granulocytes - more than 200, platelets - more than 100,000;
preserved function of the liver, kidneys, respiratory system and CCC;
the possibility of transferring an inoperable tumor process into an operable one;
refusal of the patient from the operation;
Improving long-term results of treatment with unfavorable tumor histotypes (poorly differentiated, undifferentiated).

Contraindications to chemotherapy:
Contraindications to chemotherapy can be divided into two groups: absolute and relative.
Absolute contraindications:
hyperthermia >38 degrees;
disease in the stage of decompensation (cardiovascular system, respiratory system, liver, kidneys);
the presence of acute infectious diseases;
mental illness;
The ineffectiveness of this type of treatment, confirmed by one or more specialists;
disintegration of the tumor (threat of bleeding);
Severe condition of the patient on the Karnofsky scale 50% or less

Relative contraindications:
· pregnancy;
intoxication of the body;
active pulmonary tuberculosis;
Persistent pathological changes in the composition of the blood (anemia, leukopenia, thrombocytopenia);
cachexia.

The most effective polychemotherapy regimens:
Non-small cell cancer:

Docetaxel 75 mg/m 2 on day 1
Carboplatin AIS - 5 in 1 day

Gemcitabine 1000 mg/m2 in 1; 8th days


Carboplatin - 5 in 1 day


Cisplatin 75 mg/m 2 on day 1

Cyclophosphamide 500 mg/m 2 on day 1

Vinorelbine 25 mg/m 2 on the 1st and 8th days
Cisplatin 30 mg/m 2 on days 1-3
Etoposide 80 mg/m 2 on days 1-3

Irinotecan 90 mg/m 2 on days 1 and 8
Cisplatin 60 mg/m 2 on day 1


Vinblastine 5 mg/m 2 on day 1
Cisplatin 50 mg/m 2 on day 1

Mitomycin 10 mg/m 2 on day 1
Ifosfamide (+ mesna) 2.0 g/m 2 in 1, 2, 3, 4, 5th day
Cisplatin 75 mg/m 2 on day 1
Interval between courses 2-3 weeks

Non-platinum regimens:

Gemcitabine 800 - 1000 mg / m 2 in 1; 8th days
Paclitaxel 135-175 mg/m 2 intravenously over 3 hours on day 1

Gemcitabine 800 - 1000 mg / m 2 in 1; 8th days
Docetaxel 75 mg/m 2 on day 1

Gemcitabine 800 - 1000 mg / m 2 in 1; 8th days
Pemetrexed 500mg/m2 on day 1

Paclitaxel 135-175 mg/m 2 intravenously over 3 hours on day 1
Navelbin 20-25 mg / m 2 in 1; 8th day

Docetaxel 75 mg/m 2 on day 1
Vinorelbine 20-25 mg / m 2 in 1; 8th day

Acute chemotherapy regimens for NSCLC
Cisplatin 60 mg/m 2 on day 1
Etoposide 120 mg/m 2 on days 1-3

Paclitaxel 135-175 mg/m 2 intravenously over 3 hours on day 1
Carboplatin 300 mg/m 2 intravenously over 30 minutes after paclitaxel administration on day 1
Interval between courses 21 days

Gemcitabine 1000 mg/m2 in 1; 8th day
Cisplatin 80 mg/m 2 on day 1
Interval between courses 21 days

Gemcitabine 1000 mg/m2 in 1; 8th day
Carboplatin AIS - 5 in 1 day
Interval between courses 21 days

Vinorelbine 25-30 mg / m 2 in 1; 8th day
Cisplatin 80-100 mg / m 2 on the 1st day
Interval between courses 21 - 28 days

Paclitaxel 175 mg/m 2 on day 1 for 3 hours
Cisplatin 80 mg/m 2 on day 1
Interval between courses 21 days

Docetaxel 75 mg/m 2 on day 1
Cisplatin 75 mg/m 2 on day 1
Interval between courses 21 days

Docetaxel 75 mg/m 2 on day 1
Carboplatin AIS - 5 in 1 day
Interval between courses 21 days

Pemetrexed 500mg/m2 on day 1
Cisplatin 75 mg/m 2 on day 1
Interval between courses 21 days

Chemotherapy depending on the morphological variants of NSCLC
For adenocarcinoma and bronchoalveolar lung cancer in the 1st line of chemotherapy, pemetrexed + cisplatin or paclitaxel + carboplatin regimens with or without bevacizumab have an advantage. Gemcitabine + cisplatin, docetaxel + cisplatin, vinorelbine + cisplatin are recommended for the treatment of squamous cell lung cancer.

Duration of chemotherapy for NSCLC
Based on the analysis of publications on the duration of treatment of patients with NSCLC, ASCO makes the following recommendations:
1. In first-line chemotherapy, chemotherapy should be discontinued in cases of disease progression or treatment failure after 4 cycles.
2. Treatment may be discontinued after 6 cycles, even in patients who show an effect.
3. With longer treatment, toxicity increases without any benefit to the patient.

Induction (non-adjuvant, preoperative) and adjuvant (postoperative) chemotherapy for NSCLC
The activity of various induction chemotherapy regimens (gemcitabine + cisplatin, paclitaxel + carboplatin, docetaxel + cisplatin, etoposide + cisplatin) in stage IIIA N 1-2 NSCLC is 42-65%, while 5-7% of patients have pathologically proven complete remission, and radical surgery can be performed in 75-85% of patients. Induction chemotherapy with the regimens described above is usually carried out in 3 cycles with an interval of 3 weeks. A large meta-analysis conducted in 2014 of 15 randomized controlled trials (2358 patients with stage IA-IIIA NSCLC) showed that preoperative chemotherapy increased overall survival, reducing the risk of death by 13%, which increased 5-year survival by 5% (with 40% to 45%). Progression-free survival and time to metastasis also increased.
adjuvant chemotherapy. According to the American Society of Clinical Oncology, cisplatin-based adjuvant chemotherapy may be recommended for stage IIA, IIB, and IIIA NSCLC. In stage IA and IB NSCLC, adjuvant chemotherapy has not shown a survival advantage over surgery alone and is therefore not recommended in these stages.

Supportive care
Maintenance therapy can be recommended for patients who responded to 1st line chemotherapy, as well as patients with a general condition on the ECOG-WHO scale of 0-1 points. In this case, patients should be offered a choice:
or maintenance therapy
or observation until progression
Maintenance therapy can be carried out in three ways:
1. the same combination therapy regimen that was carried out in the first line;
2. one of the drugs that was in the combination regimen (pemetrexed, gemcitabine, docetaxel);
3. targeted drug erlotinib.

Supportive therapy is carried out until the disease progresses, and only then the 2nd line of chemotherapy is prescribed.
An increase in overall survival was noted only with the use of pemetrexed. Pemetrexed at a dose of 500 mg/m 2 once every 21 days is indicated as a monotherapy for maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer who do not have disease progression after 4 cycles of first-line therapy with platinum drugs. Pemetrexed is recommended in maintenance therapy for both the "switch" and "continue" types.
The best results are achieved when using alimta in non-squamous cell carcinoma, and gemcitabine in squamous cell carcinoma with a good general condition of the patient (0-1 point), erlotinib in patients with EGFR mutations.

Choice of chemotherapy line
Patients with clinical or radiological progression after first-line chemotherapy, regardless of maintenance treatment, with PS 0-2 should be offered second-line chemotherapy.
Pemetrexed, docetaxel, erlotinib are currently recommended for second-line chemotherapy for NSCLC by the International Association for the Study of Lung Cancer and the US Food and Drug Administration (FDA). For the second line chemotherapy, etoposide, vinorelbine, paclitaxel, gemcitabine as monotherapy, as well as in combination with platinum and other derivatives, if they were not used in the first line of treatment, can also be used.
Third line HT. With the progression of the disease after the second line of chemotherapy, patients may be recommended treatment with erlotinib and gefitinib (for squamous cell lung cancer and for EGFR mutations), an EGFR tyrosine kinase inhibitor. This does not exclude the possibility of using other cytostatics for the third or fourth line that the patient has not previously received (etoposide, vinorelbine, paclitaxel, non-platinum combinations). However, patients receiving third or fourth line chemotherapy rarely achieve objective improvement, which is usually very short-lived with significant toxicity. For these patients, symptomatic therapy is the only correct method of treatment.

Targeted Therapy:
Gefitinib is a tyrosine kinase inhibitor of EGFR. Dosage regimen: 250 mg / day in the 1st line of treatment of patients with stage IIIB lung adenocarcinoma, stage IV with identified EGFR mutations. In the second line, the use of the drug with refractory to chemotherapy regimens containing platinum derivatives is justified. Duration of admission - until the progression of the disease.

Erlotinib 150mg. Use regimen - 150 mg/day orally as 1st line locally advanced or metastatic NSCLC with an active EGFR mutation, or as maintenance therapy for patients who have no signs of disease progression after 4 courses of first-line chemotherapy with platinum drugs, and also in the 2nd line after the ineffectiveness of the previous regimen of chemotherapy.

Bevacizumab is a recombinant humanized monoclonal antibody that selectively binds to and neutralizes the biological activity of human vascular endothelial growth factor VEGF. Bevacizumab is recommended for the 1st line treatment of patients with stage IIIB-IV NSCLC (non-squamous) at doses of 7.5 mg/kg body weight or 15 mg/kg once every 3 weeks until progression as part of combined chemotherapy - gemcitabine + cisplatin or paclitaxel + carboplatin.

New advances in drug therapy for NSCLC are associated with the identification of a new protein, EML-4-ALK, which is present in 3-7% of NSCLC and mutually excludes KRAS and EGFR mutations. Crizotinib is an ALK kinase inhibitor. In the presence of ALK mutations, the effectiveness of crizotinib is more than 50-60%. In the presence of ALK rearrangement, crizotinib should be considered as 2nd-line therapy because a large phase III trial comparing crizotinib with docetaxel or pemetrexed demonstrated significant benefits in terms of objective response rate and progression-free survival for crizotinib [Evidence level I, A, ESMO 2014]. Crizotinib is a new targeted drug that selectively inhibits the ALK, MET, and ROS tyrosine kinases. By suppressing the ALK-fusion protein, signaling to the cell nucleus is blocked, which leads to a cessation of tumor growth or to its reduction. Crizotinib is indicated in patients with locally advanced or metastatic NSCLC who have abnormal expression of the anaplastic lymphoma kinase (ALK) gene. In 2011, crizotinib received US FDA approval for the treatment of locally advanced or metastatic NSCLC with an ALK mutation. At the same time, the FISH test was also allowed to determine this type of mutation. Since 2014, the drug has been approved for use on the territory of the Republic of Kazakhstan.

Small cell carcinoma (SCLC):
EP
Cisplatin 80 mg/m 2 on day 1

1 time in 3 weeks

EU
Etoposide 100 mg/m 2 on days 1-3
Carboplatin AUC 5-6 per day

IP

Cisplatin 60 mg/m 2 on day 1
1 time in 3 weeks
IC
Irinotecan 60 mg/m 2 on days 1, 8 and 15
Carboplatin AUC 5-6 per day
1 time in 3 weeks

CAV

Doxorubicin 50 mg/m 2 on the 1st day

1 time in 3 weeks

CDE
Doxorubicin 45 mg/m 2 on the 1st day
Cyclophosphamide 1000 mg/m 2 on day 1
Etoposide 100 mg/m 2 on days 1,2,3 or 1, 3, 5
1 time in 3 weeks

CODE
Cisplatin 25 mg/m 2 on day 1
Vincristine 1 mg/m 2 on day 1
Doxorubicin 40 mg/m 2 on the 1st day
Etoposide 80 mg/m 2 on day 1-3
1 time in 3 weeks

Paclitaxel 135 mg/m 2 on day 1 for 3 hours
Carboplatin AUC 5-6 on day 1
1 time in 3-4 weeks

Docetaxel 75 mg/m 2 on day 1
Cisplatin 75 mg/m 2 on day 1
1 time in 3 weeks

Gemcitabine 1000 mg/m2 in 1; 8th day
Cisplatin 70 mg/m 2 on day 1
1 time in 3 weeks


Cyclophosphamide 1 g/m 2 on the 1st day
Vincristine 1.4 mg/m 2 on day 1

Vincristine 1.4 mg/m 2 on day 1
Ifosfamide 5000 mg/m 2 on day 1
Carboplatin 300 mg/m 2 on day 1
Etoposide 180 mg/m 2 in 1; 2nd day

Cyclophosphamide 1000 mg/m 2 on day 1
Doxorubicin 60 mg/m 2 on the 1st day
Methotrexate 30 mg/m 2 on day 1

Temozolomide 200 mg/m 2 on days 1-5
Cisplatin 100 mg/m 2 per day

Topotecan 2 mg/m 2 on days 1-5 and in brain MTS SCLC
Interval between courses 3 weeks

Second line chemotherapy for SCLC
Despite a certain sensitivity of SCLC to chemotherapy and radiation therapy. In most patients, there is a "relapse" of the disease, and in these cases, the choice of further treatment tactics (2nd line chemotherapy) depends on the response of patients to the 1st line of treatment, the time interval that has elapsed since its completion and the nature of the spread (localization of metastases) .
It is customary to distinguish between patients with "sensitive" relapse of SCLC (who had a complete or partial response to first-line chemotherapy and progression of the tumor process no earlier than 3 months after the end of therapy) and patients with "refractory" relapse who progressed during chemotherapy or less than 3 months after her graduation.

Criteria for assessing the prognosis and choice of tactics for the treatment of SCLC



In sensitive recurrence, it is recommended to re-apply the therapeutic regimen that was effective before. For patients with refractory relapse, it is advisable to use anticancer drugs or their combinations that were not used in previous therapy.

Tactics for the treatment of "recurrent" SCLC


In sensitive forms of SCLC, relapses are treated with reinduction therapy using the same chemotherapy regimen that was in the 1st line. For 2nd line chemotherapy, a CAV regimen or topotecan is prescribed. The CAV regimen, as already mentioned above, was previously the 1st line chemotherapy regimen for SCLC, which can now be recommended for the 1st line in cases where it is necessary to provide "urgent" care to a patient with severe shortness of breath and compression syndrome of the superior vena cava or the presence of contraindications to the use of platinum drugs. Currently, the CAV regimen has become the 2nd line of treatment for SCLC.
Patients with resistant SCLC may also receive 2nd line chemotherapy. Although the objective effect is achieved in a small percentage of patients. Chemotherapy may lead to stabilization and/or slowing of the rate of progression.

Third line chemotherapy for SCLC
The efficacy of 3rd-line chemotherapy for advanced SCLC remains unknown. Patients in the 3rd line may receive paclitaxel, gemcitabine, ifosfamide, either alone or in combination with cisplatin or carboplatin.

Targeted therapy for SCLC
Many targeted drugs have been studied in SCLC (imatinib, bevacizumab, sorafenib, everolimus, erlotinib, gefitinib), but none of them has changed the clinical approaches and treatment options for this disease and has not led to an increase in the life of patients.

Surgical intervention.
Surgical intervention provided on an outpatient basis: not performed.

Surgical intervention provided at the hospital level:
Radical surgery is the method of choice in the treatment of patients with stages I-II and operable patients with stage IIIa lung cancer.
Standard operations are lobectomy, bilobectomy or pneumonectomy with the removal of all affected and unaffected lymph nodes of the root of the lung and mediastinum from the surrounding tissue on the side of the lesion (extended operations) and combined operations are performed (removal of tumor-affected areas of neighboring organs and mediastinum). With solitary and single (up to 4 formations) metastatic formations, it is advisable to perform operations using the precision technique (precision resection).
All operations performed on the lungs must be accompanied by lymph node dissection, which includes: bronchopulmonary, bifurcation, paratracheal, paraaortic, paraesophageal and lymph nodes of the pulmonary ligament (extended lobectomy, bilobectomy and pneumonectomy).
The volume of surgical intervention is determined by the degree of spread and localization of the tumor lesion. Damage within the parenchyma of one lobe or localization of the proximal edge of the carcinoma at the level of segmental bronchi or distal parts of the lobar and main bronchus is the basis for performing lobectomy, bilobectomy and pneumonectomy.
Note. In case of a tumor lesion of the mouth of the upper lobe and intermediate bronchus of the right lung, less often the left lung, reconstructive plastic surgery should be performed. If the mouth of the main bronchi, bifurcation or lower third of the trachea on the right is involved in the process, reconstructive plastic surgery should also be performed.

adjuvant therapy
Radically operated patients with non-small cell lung cancer with metastases to the mediastinal lymph nodes in the postoperative period undergo adjuvant radiation therapy to the mediastinal region and the root of the opposite lung in a total dose of 40 Gy (2 Gy per fraction, 20 fractions) + polychemotherapy.
Radically operated patients with small cell lung cancer in the postoperative period undergo courses of adjuvant polychemotherapy.

Treatment of relapses and metastases of lung cancer:
· Surgical
In case of postoperative recurrence of cancer or single intrapulmonary metastases (up to 4 formations), with a satisfactory general condition and laboratory parameters, a second operation is indicated.

· Chemoradiation
I.Relapse in the mediastinum and supraclavicular lymph nodes
With relapse in the mediastinum and supraclavicular lymph nodes, palliative radiation or chemoradiotherapy is performed. The radiation therapy program depends on the previous treatment. If the radiation component was not used at the previous stages, then a course of radiation therapy is carried out according to a radical program according to one of the methods described above, depending on the morphological form of the tumor. If radiation therapy was used in one volume or another at the previous stages of treatment, we are talking about additional radiation therapy, the effect of which can be realized only when doses of at least 30-40 Gy are applied. An additional course of radiation therapy is carried out ROD 2 Gy, SOD up to 30-60 Gy, depending on the timing after the completion of the previous exposure + polychemotherapy.

II.Metastases in the brain
Single brain metastases can be removed with subsequent irradiation. If surgical removal is not possible, brain irradiation is performed.
Radiation therapy should be started only if there are no signs of increased intracranial pressure (examination by an ophthalmologist, neurologist). Irradiation is carried out against the background of dehydration (mannitol, sarmanthol, diuretics), as well as corticosteroids.
First, the entire brain is irradiated in ROD 2 Gy, SOD 20 Gy, then aiming at the metastasis area ROD 2 Gy, SOD 40 Gy + polychemotherapy.

III. Second metachronous lung cancer or lung metastases

A single tumor node in the lung that appeared after radical treatment, in the absence of other signs of progression, should be considered as a second metachronous lung cancer, subject, if possible, to surgical removal. With multiple formations, chemoradiotherapy is performed.

IV.Metastatic bone disease
Local irradiation of the affected area is carried out. In case of damage to the spine, one adjacent healthy vertebra is additionally included in the irradiated volume. When a metastatic lesion is localized in the cervical and thoracic regions, ROD is 2 Gy, SOD is 40 Gy with an irradiation field length of more than 10 cm. In case of damage to other bones of the skeleton, SOD is 60 Gy, taking into account the tolerance of surrounding normal tissues.

The effect of the treatment is assessed according to the classification criteriaRECIST:
full effect- disappearance of all lesions for a period of at least 4 weeks;
partial effect- reduction of foci by 30% or more;
Progression- an increase in the focus by 20%, or the appearance of new foci;
Stabilization- no tumor reduction less than 30%, and an increase of more than 20%.

Other types of treatment.
Radiation therapy can be used alone or in combination with polychemotherapy.
Types of radiation therapy:
convection
comfortable
Indications for radiotherapy:
radical surgical treatment is not indicated due to the functional state
when the patient refuses surgical treatment
when the process is inoperable

Contraindications for radiotherapy:
The presence of decay in the tumor
constant bleeding
Presence of exudative pleurisy
Severe infectious complications (pleural empyema, abscess formation in atelectasis)
active form of pulmonary tuberculosis
Stage III diabetes mellitus
Concomitant diseases of vital organs in the stage of decompensation (cardiovascular system, lungs, liver, kidneys)
acute inflammatory diseases
An increase in body temperature over 38 ° C
Severe general condition of the patient (on the Karnofsky scale 40% or less)

The method of radiation therapy according to the radical program of non-small cell lung cancer:
All patients with non-small cell cancer receive external beam radiation therapy to the area of ​​the primary focus and the area of ​​regional metastasis. For radiation treatment, the quality of radiation, localization and size of the fields are necessarily taken into account. The volume of irradiation is determined by the size and localization of the tumor and the area of ​​regional metastasis and includes the tumor + 2 cm of tissue outside its borders and the area of ​​regional metastasis.
The upper border of the field corresponds to the jugular notch of the sternum. Lower limit: with a tumor of the upper lobe of the lung - 2 cm below the bifurcation of the trachea; with a tumor of the middle lobe of the lung and the absence of metastases in the bifurcation lymph nodes - 4 cm below the bifurcation of the trachea; with a tumor of the middle lobe of the lung and the presence of metastases in the bifurcation lymph nodes, as well as with a tumor of the lower lobe of the lung - the upper level of the diaphragm.
With a low degree of differentiation of epidermoid and glandular lung cancer, the cervical-supraclavicular zone on the side of the lesion is additionally irradiated.
Treatment is carried out in 2 stages with an interval between them of 2-3 weeks. At the first stage, ROD 2 Gr, SOD 40 Gr. At the second stage, irradiation is carried out from the same fields (the part of the field, including the primary focus, can be reduced according to the decrease in the size of the primary tumor), ROD 2 Gy, SOD 20 Gy.

Method of chemoradiotherapy for small cell lung cancer:

Special treatment of patients with small cell lung cancer begins with a course of polychemotherapy. After 1-5 days (depending on the patient's condition), remote radiation therapy is performed with the inclusion in the volume of irradiation of the primary tumor, mediastinum, roots of both lungs, cervical-supraclavicular zones on both sides. The radiation therapist determines the technical conditions for irradiation.
Remote radiation therapy is carried out in 2 stages. At the 1st stage, the treatment is ROD 2 Gy, 5 fractions, SOD 20 Gy. At the 2nd stage (without interruption) ROD 2 Gr, SOD 40 Gr.
For prophylactic purposes, both cervical-supraclavicular zones are irradiated from one anterior field with a central block along the entire length of the field to protect the cartilage of the larynx and cervical spinal cord. Radiation therapy is carried out ROD 2 Gy, SOD 40 Gy. In case of metastatic lesions of the supraclavicular lymph nodes, additional irradiation of the affected area is performed from the local field ROD 2 Gy, SOD 20 Gy.
After the main course of special treatment, courses of adjuvant polychemotherapy are carried out with an interval of 3 weeks. At the same time, rehabilitation measures are carried out, including anti-inflammatory and restorative treatment.

Palliative radiotherapy:

Syndrome of compression of the superior vena cava

1. In the absence of severe difficulty in breathing and the width of the tracheal lumen is more than 1 cm, treatment (in the absence of contraindications) begins with polychemotherapy. Then radiation therapy is carried out:
With non-small cell lung cancer ROD 2 Gy, SOD 40 Gy. After 3-4 weeks, the issue of the possibility of continuing radiation treatment (ROD 2 Gy, SOD 20 Gy) is decided. In small cell lung cancer, treatment is carried out continuously up to SOD 60 Gy.
2. With severe shortness of breath and the width of the lumen of the trachea is less than 1.0 cm, treatment begins with radiation therapy ROD 0.5-1 Gy. In the process of treatment, with a satisfactory condition of the patient, a single dose is increased to 2 Gy, SOD 50-60 Gy.

· Distant metastases
Ioption. With a satisfactory condition of the patient and the presence of single metastases, radiation therapy is performed on the zones of the primary focus, regional metastasis and distant metastases + polychemotherapy.
IIoption. In severe condition of the patient, but not less than 50% on the Karnofsky scale (see Appendix 1) and the presence of multiple distant metastases, radiation therapy is performed locally on the areas of the most pronounced lesion in order to relieve shortness of breath, pain syndrome + polychemotherapy.

Palliative Care:
«

Other types of treatment provided at the outpatient level: radiation therapy

Other types of treatment provided at the inpatient level: radiation therapy.

Palliative Care:
In case of severe pain syndrome, treatment is carried out in accordance with the recommendations of the protocol « Palliative care for patients with chronic progressive diseases in the incurable stage, accompanied by chronic pain syndrome, approved by the minutes of the meeting of the Expert Commission on Health Development of the Ministry of Health of the Republic of Kazakhstan No. 23 dated December 12, 2013.
In the presence of bleeding, treatment is carried out in accordance with the recommendations of the protocol "Palliative care for patients with chronic progressive diseases in an incurable stage, accompanied by bleeding", approved by the protocol of the meeting of the Expert Commission on Health Development of the Ministry of Health of the Republic of Kazakhstan No. 23 dated December 12, 2013.

Other types of treatment provided at the ambulance stage: No.

Treatment effectiveness indicators:
Tumor response - tumor regression after treatment;
recurrence-free survival (three and five years);
· "quality of life" includes, in addition to the psychological, emotional and social functioning of a person, the physical condition of the patient's body.

Further management:
Dispensary observation of cured patients:
during the first year after completion of treatment - 1 time every 3 months;
during the second year after completion of treatment - 1 time every 6 months;
from the third year after completion of treatment - 1 time per year for 5 years.
Examination methods:
· General blood analysis
Biochemical blood test (protein, creatinine, urea, bilirubin, ALT, AST, blood glucose)
Coagulogram (prothrombin index, fibrinogen, fibrinolytic activity, thrombotest)
X-ray of the chest organs (2 projections)
Computed tomography of the chest and mediastinum

Drugs (active substances) used in the treatment
Bevacizumab (Bevacizumab)
Vinblastine (Vinblastine)
Vincristine (Vincristine)
Vinorelbine (Vinorelbine)
Gemcitabine (Gemcitabine)
Gefitinib (Gefitinib)
Doxorubicin (Doxorubicin)
Docetaxel (Docetaxel)
Imatinib (Imatinib)
Irinotecan (Irinotecan)
Ifosfamide (Ifosfamide)
Carboplatin (Carboplatin)
Crizotinib (Crizotinib)
Mitomycin (Mitomycin)
Paclitaxel (Paclitaxel)
Pemetreksed (Pemetreksed)
Temozolomide (Temozolomide)
Topotecan (Topotecan)
Cyclophosphamide (Cyclophosphamide)
Cisplatin (Cisplatin)
Everolimus (Everolimus)
Erlotinib (Erlotinib)
Etoposide (Etoposide)

Hospitalization


Indications for hospitalization, indicating the type of hospitalization:

Indications for planned hospitalization:
The presence of a tumor process, verified histologically and/or cytologically. Operable lung cancer (stages I-III).

Indications for emergency hospitalization: No.

Prevention


Preventive actions
The use of drugs that allow you to restore the immune system after antitumor treatment (antioxidants, multivitamin complexes), a complete diet rich in vitamins, proteins, giving up bad habits (smoking, drinking alcohol), preventing viral infections and concomitant diseases, regular preventive examinations by an oncologist, regular diagnostic procedures (radiography of the lungs, ultrasound of the liver, kidneys, lymph nodes of the neck)

Information

Sources and literature

  1. Minutes of the meetings of the Expert Council of the RCHD MHSD RK, 2015
    1. References 1. Standards for the treatment of malignant tumors (Russia), Chelyabinsk, 2003. 2. Trakhtenberg A.Kh. Clinical onco-pulmonology. Geomretar, 2000. 3. TNM Classification of malignant tumors. Sobin L.Kh., Gospordarovich M.K., Moscow 2011 4. Neuroendocrine tumors. Guide for doctors. Edited by Martin Caplin, Larry Kvols/ Moscow 2010 5. European Society for Medical Oncology (ESMO) minimum clinical guidelines 6. American Joint Committee on Cancer (AJCC). AJCC Cancer Staging Manual, 7th ed. Edge S.B., Byrd D.R., Carducci M.A. et al., eds. New York: Springer; 2009; 7. Guidelines for chemotherapy of neoplastic diseases, edited by N.I. Perevodchikova, V.A. Gorbunova. Moscow 2015 8. The chemotherapy Source Book, Fourth Edition, Michael C. Perry 2008 by Lip-pincot Williams 9. Journal of Clinical Oncology Vol. 2, no. 3, p. 235, “Carcinoid” 100 years later: epidemiology and prognostic factors of neuroendocrine tumors. 10. Ardill JE. Circulating markers for endocrine tumors of the gastroenteropancreatic tract. Ann Clin Biochem. 2008; 539-59 11. Arnold R, Wilke A, Rinke A, et al. Plasma chromogranin A as a marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol. 2008, pp. 820-7

Information


List of protocol developers with qualification data:

1. Karasaev Makhsot Ismagulovich - Candidate of Medical Sciences, RSE on REM "Kazakh Research Institute of Oncology and Radiology", head of the Center for Thoracic Oncology.
2. Baimukhametov Emil Targynovich - Doctor of Medical Sciences, RSE on REM "Kazakh Research Institute of Oncology and Radiology", doctor of the Center for Thoracic Oncology.
3. Kim Viktor Borisovich - Doctor of Medical Sciences, RSE on REM "Kazakh Research Institute of Oncology and Radiology", head of the Center for Neurooncology.
4. Abdrakhmanov Ramil Zufarovich - Candidate of Medical Sciences, RSE on REM "Kazakh Research Institute of Oncology and Radiology", head of the chemotherapy day hospital.
5. Tabarov Adlet Berikbolovich - clinical pharmacologist, RSE on REM "Hospital of the Medical Center Administration of the President of the Republic of Kazakhstan", head of the department of innovation management.

Statement of conflict of interest: No

Reviewers: Kaydarov Bakhyt Kasenovich - Doctor of Medical Sciences, Professor, Head of the Department of Oncology of the Republican State Enterprise on the REM “S.D. Asfendiyarov";

Indication of the conditions for revising the protocol: revision of the protocol 3 years after its publication and from the date of its entry into force or in the presence of new methods with a level of evidence.

Annex 1
Assessment of the general condition of the patient using the Karnofsky index

Normal physical activity, the patient does not need special care 100 points The condition is normal, there are no complaints and symptoms of the disease
90 points Normal activity is preserved, but there are minor symptoms of the disease.
80 points Normal activity is possible with additional efforts, with moderate symptoms of the disease.
Restriction of normal activity while maintaining complete independence
sick
70 points Patient is self-supporting but unable to perform normal activities or work
60 points The patient sometimes needs help, but mostly takes care of himself.
50 points The patient often needs help and medical care.
The patient cannot serve himself independently, care or hospitalization is necessary 40 points Most of the time the patient spends in bed, requires special care and assistance.
30 points The patient is bedridden, hospitalization is indicated, although the terminal state is not necessary.
20 points Severe manifestations of the disease require hospitalization and supportive care.
10 points Dying patient, rapid progression of the disease.
0 points Death.

Attached files

Attention!

  • By self-medicating, you can cause irreparable harm to your health.
  • The information posted on the MedElement website and in the mobile applications "MedElement (MedElement)", "Lekar Pro", "Dariger Pro", "Diseases: Therapist's Handbook" cannot and should not replace a face-to-face consultation with a doctor. Be sure to contact medical facilities if you have any diseases or symptoms that bother you.
  • The choice of drugs and their dosage should be discussed with a specialist. Only a doctor can prescribe the right medicine and its dosage, taking into account the disease and the condition of the patient's body.
  • The MedElement website and mobile applications "MedElement (MedElement)", "Lekar Pro", "Dariger Pro", "Diseases: Therapist's Handbook" are exclusively information and reference resources. The information posted on this site should not be used to arbitrarily change the doctor's prescriptions.
  • The editors of MedElement are not responsible for any damage to health or material damage resulting from the use of this site.

Today, lung cancer is considered the most common oncological pathology with a high degree of mortality. Previously, this disease was the prerogative of people of the older age group, but now cancer is “younger”. Modern diagnostic methods make it possible to detect the disease at an early stage, which greatly facilitates the treatment process. In lung cancer, an integrated approach is used, which includes chemotherapy, radiation therapy and surgery. Chemotherapy for lung cancer is highly effective and significantly increases the chances of recovery.

What is lung cancer

Every year, up to a million cases of lung cancer are diagnosed worldwide. The statistics regarding a positive prognosis are disappointing - 6 fatal episodes per 10 cases. On the territory of the Russian Federation, this figure is 12% of the total morbidity, while mortality is 15% of all detected cases.

Lung cancer is prevalent predominantly among the male population. Oncologists explain this distribution by the causes that led to the pathological process - smoking.

The classification is based on the localization of the pathological focus:

  • central - located in the lumen of the large bronchi in the roots of the lung. As it develops, it leads to complete overlap, as a result, the lung cannot function normally;
  • peripheral - an extremely dangerous option, since it occupies the area along the edge of the lung fields, remains “dumb” for a very long time, makes itself felt only with a significant increase in size;
  • massive - a combined lesion with both options.

Stages of cancer development

There are 4 main stages in the development of the lung cancer process, while the third is divided into 2 subtypes:

  1. Zero. At an early stage, the formation of pathological cells occurs, which are not determined by instrumental methods. Clinical manifestations in the zero stage are not detected.
  2. First. The most favorable for the appointment of therapy, since treatment during this period can bring the maximum positive effect. The size of the focus does not exceed three centimeters in maximum length. Reactions of regional lymph nodes are not noted. Cancer is detected at the first stage in only 10%, which determines the importance of annual fluorographic examinations.
  3. Second. The size of the tumor node varies in the range from 3 to 5 centimeters, which allows them to be visualized on x-rays. Accompanied by specific complaints - cough, hemoptysis, syndromes from the cardiovascular system, weight loss, increased fatigue.
  4. Stage 3a. The size of the tumor increases, which leads to an increase in symptoms. Involvement of lymph nodes of a mediastinum is noted. The favorable prognosis is about 30%.
  5. Stage 3b. Metastases appear both in the lung itself and in the vertebrae of the thoracic region, ribs, and sternum. May be accompanied by pathological fractures.
  6. Fourth. Multiple foci of dropouts that spread hematogenously. The chances of recovery are minimal, so chemotherapy may often not be prescribed for stage 4 lung cancer. In such a situation resort to symptomatic treatment (palliative).

Based on this division, oncologists select the type of therapy.

Therapeutic measures for lung cancer

Early diagnosis provides a favorable prognosis for cure. For this purpose, a screening method is used - fluorography. If a pathological focus is detected, they are sent for an additional examination - computed tomography. If the fact of cancer according to CT data is confirmed, then the next step is histology in order to determine the type of cells.

Based on the results of all studies, a complex of therapeutic measures is being created. The main methods for lung cancer are surgery, chemotherapy and radiation therapy. It is an integrated approach with the use of all techniques that can give a positive effect.

Surgical treatment of lung cancer

The purpose of the operation is to remove the maximum volume of the tumor node in order to reduce compression on adjacent tissues. To achieve a significant effect, it is always combined with chemotherapy and radiation therapy.

There are several approaches to surgical intervention (laparoscopically, transthoracically), which depend on the type, size and location of the tumor.

Chemotherapy

It is the main treatment for cancer. The mechanism of action of drugs is based on a massive effect on the cellular apparatus of the tumor with its destruction. Depending on the combination with the surgical approach, chemotherapy for lung cancer is of three types:

  1. Neoadjuvant, which is prescribed before surgery. Designed to destroy tumor cells, stop metastasis.
  2. Adjuvant, used after surgery or radiation therapy for the final elimination of the remaining elements of cancer.
  3. Targeted - a high-precision technique based on a targeted effect on the node with inhibition of growth and division. There is also a restriction of the blood supply to the cancer. The technique can be used both as an independent therapy and in combination with other options.

Indications and contraindications for chemotherapy

The conditions for choosing such an approach are:

  • localization of the node and the degree of impact on the surrounding tissues;
  • the types of cells that formed the tumor;
  • the presence of intraorgan and distant metastases;
  • lymph node response.

Leukemia, rhabdomyosarcoma, hemoblastosis, chorioncarcinoma allow for a course of chemo for lung cancer.

Before starting treatment, the doctor assesses the risks, expected side effects. A well-designed course of chemotherapy increases the likelihood of a successful cure.

Contraindications for chemotherapy:

  • thrombocytopenia;
  • infectious diseases in the acute period;
  • pregnancy, especially in the first trimester;
  • renal, hepatic, heart failure;
  • marked exhaustion.

The peculiarity of these contraindications is the possibility of correction. Therefore, the attending physician will initially remove the restrictions, and then begin specific chemotherapy treatment.

Drug Options During Chemotherapy

There are more than 60 options for drugs that are used during chemotherapy. The most common are Cisplatin, Carboplatin, Gemcitabine, Vinorelbine, Paclitaxel and Docetaxel. Most often create combinations of them.

The development of the science of oncology does not stand still; new cytostatic drugs are being created. It is possible that during the course of treatment you may be offered participation in clinical trials. Of course, you have the right to refuse.

Conditions for chemotherapy

Chemistry (cytostatics) for lung cancer is most often administered intravenously in a hospital setting. The doctor selects the regimen and dose, based on the histological appearance of the tumor, the stage of the disease and the individual characteristics of the patient.

Upon completion of the course of chemotherapy, the patient is given a break for recovery for 2 weeks. Then the next course will follow, their number is determined by the protocol of therapy and effectiveness. Repeated conduct is due to the adaptive characteristics of cancer cells to the toxic effects of drugs. To smooth side effects, symptomatic therapy is prescribed.

There is also a tablet option for taking chemotherapy drugs. The advantage is that you can drink them on an outpatient basis.

Side effects

The effectiveness of this method is very high, especially with early detection. A feature of the drugs of the standard scheme is an indiscriminate effect on the cells of the body. Therefore, the consequences of chemotherapy for lung cancer are reflected in all systems:

  • hematopoiesis (blood formation);
  • violations of the functioning of the gastrointestinal tract in the form of dyspeptic manifestations;
  • a massive effect of drugs on all rapidly dividing cells (not just cancer cells) is accompanied by hair loss (alopecia);
  • psycho-emotional disorders (depression);
  • the addition of secondary infections due to a decrease in the protective functions of the body is not excluded.

It is important to understand that these manifestations are inevitable, they must be taken for granted. On the other hand, they are temporary. Quite often, after completing the courses, all physiological processes return to normal. This period in life must be experienced and in no case should the treatment be stopped.

palliative care

A new direction in the management of patients is palliative chemotherapy for lung cancer. This approach is used for a group of patients to whom all possible methods have been provided, but the process is constantly progressing. It is intended to improve the quality of life of inoperable patients by leveling pain syndromes, correcting the psycho-emotional background.

Radiotherapy

Based on the effect of a beam of gamma rays on the tumor process. At the same time, the death of cancer cells is noted due to cessation of growth and division. The rays affect not only the tumor itself, but also adjacent metastases, which gives a complex effect. The use of radiotherapy is also possible for small cell lung cancer. Recent medical advances in radiotherapy include:

  • remote technique, when the impact is carried out using an external (outside the body) source of x-rays;
  • high-dose technology, which is based on the introduction into the patient's body of a special source that generates rays.

The latest advancement is the RAPID Arc therapy. The peculiarity is the point impact exclusively on the cancer node, while healthy tissues are not damaged.. It is accompanied by visual control of the manipulation with the ability to adjust the flow intensity and direction angle. The application is limited by the prevalence of the process.

If the cancer goes beyond the lungs, then this technique is not carried out.

conclusions

Lung cancer is a terrible disease with a high mortality rate. It is impossible to cure this disease on your own. Expectant tactics are fraught with an increase in the tumor to the point where the methods of modern medicine cannot help.

Chemotherapy is a recognized and effective method of preventing the further development of oncology. Of course, it has a number of side effects, but the effectiveness successfully covers them.

Similar posts